CovAID : Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases
Copyright © 2023 Chevalier, Genin, Jean, Avouac, Flipo, Georgin-Lavialle, El Mahou, Pertuiset, Pham, Servettaz, Marotte, Domont, Chazerain, Devaux, Mekinian, Sellam, Fautrel, Rouzaud, Ebstein, Costedoat-Chalumeau, Richez, Hachulla, Mariette and Seror..
Introduction: Autoimmune/inflammatory rheumatic diseases (AIRDs) patients might be at-risk of severe COVID-19. However, whether this is linked to the disease or to its treatment is difficult to determine. This study aimed to identify factors associated with occurrence of severe COVID-19 in AIRD patients and to evaluate whether having an AIRD was associated with increased risk of severe COVID-19 or death.
Materials and methods: Two databases were analyzed: the EDS (Entrepôt des Données de Santé, Clinical Data Warehouse), including all patients followed in Paris university hospitals and the French multi-center COVID-19 cohort [French rheumatic and musculoskeletal diseases (RMD)]. First, in a combined analysis we compared patients with severe and non-severe COVID-19 to identify factors associated with severity. Then, we performed a propensity matched score case-control study within the EDS database to compare AIRD cases and non-AIRD controls.
Results: Among 1,213 patients, 195 (16.1%) experienced severe COVID-19. In multivariate analysis, older age, interstitial lung disease (ILD), arterial hypertension, obesity, sarcoidosis, vasculitis, auto-inflammatory diseases, and treatment with corticosteroids or rituximab were associated with increased risk of severe COVID-19. Among 35,741 COVID-19 patients in EDS, 316 having AIRDs were compared to 1,264 Propensity score-matched controls. AIRD patients had a higher risk of severe COVID-19 [aOR = 1.43 (1.08-1.87), p = 0.01] but analysis restricted to rheumatoid arthritis and spondyloarthritis found no increased risk of severe COVID-19 [aOR = 1.11 (0.68-1.81)].
Conclusion: In this multicenter study, we confirmed that AIRD patients treated with rituximab or corticosteroids and/or having vasculitis, auto-inflammatory disease, and sarcoidosis had increased risk of severe COVID-19. Also, AIRD patients had, overall, an increased risk of severe COVID-19 compares general population.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Frontiers in medicine - 10(2023) vom: 05., Seite 1152587 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chevalier, Kevin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Auto-immune diseases |
|---|
| Anmerkungen: |
Date Revised 02.11.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fmed.2023.1152587 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355399598 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355399598 | ||
| 003 | DE-627 | ||
| 005 | 20231226064249.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fmed.2023.1152587 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355399598 | ||
| 035 | |a (NLM)37035330 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chevalier, Kevin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CovAID |b Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.11.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2023 Chevalier, Genin, Jean, Avouac, Flipo, Georgin-Lavialle, El Mahou, Pertuiset, Pham, Servettaz, Marotte, Domont, Chazerain, Devaux, Mekinian, Sellam, Fautrel, Rouzaud, Ebstein, Costedoat-Chalumeau, Richez, Hachulla, Mariette and Seror. | ||
| 520 | |a Introduction: Autoimmune/inflammatory rheumatic diseases (AIRDs) patients might be at-risk of severe COVID-19. However, whether this is linked to the disease or to its treatment is difficult to determine. This study aimed to identify factors associated with occurrence of severe COVID-19 in AIRD patients and to evaluate whether having an AIRD was associated with increased risk of severe COVID-19 or death | ||
| 520 | |a Materials and methods: Two databases were analyzed: the EDS (Entrepôt des Données de Santé, Clinical Data Warehouse), including all patients followed in Paris university hospitals and the French multi-center COVID-19 cohort [French rheumatic and musculoskeletal diseases (RMD)]. First, in a combined analysis we compared patients with severe and non-severe COVID-19 to identify factors associated with severity. Then, we performed a propensity matched score case-control study within the EDS database to compare AIRD cases and non-AIRD controls | ||
| 520 | |a Results: Among 1,213 patients, 195 (16.1%) experienced severe COVID-19. In multivariate analysis, older age, interstitial lung disease (ILD), arterial hypertension, obesity, sarcoidosis, vasculitis, auto-inflammatory diseases, and treatment with corticosteroids or rituximab were associated with increased risk of severe COVID-19. Among 35,741 COVID-19 patients in EDS, 316 having AIRDs were compared to 1,264 Propensity score-matched controls. AIRD patients had a higher risk of severe COVID-19 [aOR = 1.43 (1.08-1.87), p = 0.01] but analysis restricted to rheumatoid arthritis and spondyloarthritis found no increased risk of severe COVID-19 [aOR = 1.11 (0.68-1.81)] | ||
| 520 | |a Conclusion: In this multicenter study, we confirmed that AIRD patients treated with rituximab or corticosteroids and/or having vasculitis, auto-inflammatory disease, and sarcoidosis had increased risk of severe COVID-19. Also, AIRD patients had, overall, an increased risk of severe COVID-19 compares general population | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a auto-immune diseases | |
| 650 | 4 | |a inflammatory rheumatic diseases | |
| 650 | 4 | |a lupus | |
| 650 | 4 | |a rheumatic and musculoskeletal diseases | |
| 650 | 4 | |a rituximab | |
| 650 | 4 | |a vasculitis | |
| 700 | 1 | |a Genin, Michaël |e verfasserin |4 aut | |
| 700 | 1 | |a Jean, Thomas Petit |e verfasserin |4 aut | |
| 700 | 1 | |a Avouac, Jerôme |e verfasserin |4 aut | |
| 700 | 1 | |a Flipo, Rene-Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Georgin-Lavialle, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a El Mahou, Soumaya |e verfasserin |4 aut | |
| 700 | 1 | |a Pertuiset, Edouard |e verfasserin |4 aut | |
| 700 | 1 | |a Pham, Thao |e verfasserin |4 aut | |
| 700 | 1 | |a Servettaz, Amelie |e verfasserin |4 aut | |
| 700 | 1 | |a Marotte, Hubert |e verfasserin |4 aut | |
| 700 | 1 | |a Domont, Fanny |e verfasserin |4 aut | |
| 700 | 1 | |a Chazerain, Pascal |e verfasserin |4 aut | |
| 700 | 1 | |a Devaux, Mathilde |e verfasserin |4 aut | |
| 700 | 1 | |a Mekinian, Arsene |e verfasserin |4 aut | |
| 700 | 1 | |a Sellam, Jérémie |e verfasserin |4 aut | |
| 700 | 1 | |a Fautrel, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Rouzaud, Diane |e verfasserin |4 aut | |
| 700 | 1 | |a Ebstein, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Costedoat-Chalumeau, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Richez, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Hachulla, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Mariette, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Seror, Raphaèle |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in medicine |d 2014 |g 10(2023) vom: 05., Seite 1152587 |w (DE-627)NLM245390847 |x 2296-858X |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2023 |g day:05 |g pages:1152587 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fmed.2023.1152587 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2023 |b 05 |h 1152587 | ||